ProCE Banner Activity

An Updated Interactive Treatment Decision Support Tool for Follicular Lymphoma

Clinical Thought
Read this expert commentary for an overview of our updated treatment decision support tool for follicular lymphoma that provides treatment recommendations from 5 lymphoma experts for your patients with newly diagnosed and relapsed/refractory disease.

Released: March 18, 2021

Expiration: March 17, 2022

Share

Faculty

Christopher R. Flowers

Christopher R. Flowers, MD, MS

Department Chair
Department of Lymphoma/Myeloma, Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bayer Healthcare Pharma

Celgene

Epizyme, Inc.

Faculty Disclosure

Primary Author

Christopher R. Flowers, MD, MS

Department Chair
Department of Lymphoma/Myeloma, Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Christopher R. Flowers, MD, MS, has disclosed that he has received consulting fees from AbbVie, Bayer, BeiGene, Celgene, Denovo Biopharma, Genentech/Roche, Gilead Sciences, Karyopharm, MEI Pharmaceuticals, Pharmacyclics/Janssen, and Spectrum; has received funds for research support from AbbVie, Acerta, Celgene, Gilead Sciences, Genentech/Roche, CPRIT, Janssen, Millennium/Takeda, Pharmacyclics, Therapeutics, Burroughs Welcome Fund, ECOG, NCI, and V Foundation.